Frankfurt
10.04.26 | 17:08
0,586 Euro
+16,97 % +0,085
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Egetis Therapeutics: Egetis Appoints Tiago Nunes as Chief Medical Officer | 321 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer... ► Artikel lesen | |
| 27.03. | Egetis Therapeutics: Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate for MCT8 Deficiency | 452 | ACCESS Newswire | NDA submission for Emcitate successfully validated by the FDAPriority Review granted and PDUFA target action date set to September 28, 2026Emcitate (tiratricol) is eligible to receive a Priority Review... ► Artikel lesen | |
| 09.03. | Egetis Therapeutics: Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S. | 374 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office... ► Artikel lesen | |
| 02.03. | Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers | 300 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / March 2, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced the launch of two updated educational websites... ► Artikel lesen | |
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.02. | Egetis Therapeutics AB: Year-End Report January-December 2025 | 198 | GlobeNewswire (Europe) | Egetis submitted the U.S. NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency· Emcitate® revenue during 2025 amounted to MSEK 62.3, a 40 % increase in constant exchange rates from... ► Artikel lesen | |
| 16.02. | Egetis Therapeutics AB: Egetis provides update on progress with the development of Emcitate (tiratricol) for MCT8 deficiency in Japan | 220 | GlobeNewswire (Europe) | Stockholm, Sweden, February 16, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that its Japanese partner Fujimoto Pharmaceuticals, who has... ► Artikel lesen | |
| 04.02. | Egetis Therapeutics AB: FDA's rare pediatric disease priority review program extended until 2029 | 234 | GlobeNewswire (Europe) | Stockholm, Sweden, February 4, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today noted that the U.S. Food and Drug Administration's (FDA's) Rare Pediatric... ► Artikel lesen | |
| 29.01. | Egetis Therapeutics AB: Egetis Completes the U.S. Rolling NDA Submission for Emcitate (tiratricol) for Treatment of MCT8 Deficiency | 176 | GlobeNewswire (Europe) | Priority Review and Rare Pediatric Disease Priority Review Voucher requestedAnticipated regulatory decision in September 2026Emcitate® (tiratricol) U.S. launch expected in Q4 2026, if approvedStockholm... ► Artikel lesen | |
| 19.12.25 | Egetis Therapeutics AB: Egetis Therapeutics initiates New Drug Application in the USA for Emcitate (tiratricol) for MCT8 deficiency | 262 | GlobeNewswire (Europe) | Stockholm, Sweden, December 19, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company has initiated a rolling New Drug Application... ► Artikel lesen | |
| 10.12.25 | Egetis Therapeutics AB: Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate Across Central, Eastern, and Southeastern Europe | 189 | GlobeNewswire (Europe) | Stockholm, Sweden, December 10, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company, through its wholly-owned subsidiary Rare Thyroid... ► Artikel lesen | |
| 25.11.25 | Egetis-Aktie unter Druck: Positive Studiendaten können Kursverlust nach Q3-Zahlen nicht verhindern | 4 | Investing.com Deutsch | ||
| 25.11.25 | Egetis Therapeutics AB: Interim report Q3 2025 | 211 | GlobeNewswire (Europe) | Egetis to commence a rolling NDA submission in December as granted by the FDA for Emcitate® (tiratricol)· Egetis received FDA Breakthrough Therapy Designation for Emcitate® (tiratricol) for... ► Artikel lesen | |
| 14.11.25 | Egetis Therapeutics AB: Egetis announces positive results from the ReTRIACt study of Emcitate (tiratricol) in MCT8 deficiency | 174 | GlobeNewswire (Europe) | Positive topline results demonstrate a statistically significant (p=0.034) difference in the rate of change in serum T3 in patients randomized to withdrawal (placebo) vs. in patients continuing therapy... ► Artikel lesen | |
| 23.10.25 | Egetis Therapeutics AB: Egetis granted a rolling NDA review by FDA for Emcitate (tiratricol) based on currently available clinical data | 283 | GlobeNewswire (Europe) | The outcomes of a successful pre-NDA meeting with the FDA are:
As agreed with the FDA, the rolling NDA submission will commence in December 2025, targeting a complete NDA submission in early 2026 and... ► Artikel lesen | |
| 02.10.25 | Egetis Therapeutics AB: Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares | 225 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 21.08.25 | Egetis Therapeutics AB: Interim report Q2 2025 | 277 | GlobeNewswire (Europe) | Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis... ► Artikel lesen | |
| 18.08.25 | Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol | 556 | GlobeNewswire (Europe) | FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by... ► Artikel lesen | |
| 15.07.25 | Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency | 399 | GlobeNewswire (Europe) | Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... ► Artikel lesen | |
| 05.05.25 | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 569 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
| 30.04.25 | Egetis Therapeutics AB: Interim report Q1 2025 | 258 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,120 | -0,82 % | Evotec holt früheren Bayer-Vorstand Weinand als Aufsichtsratschef | DJ Evotec holt früheren Bayer-Vorstand Weinand als Aufsichtsratschef
DOW JONES--Evotec bekommt einen neuen Aufsichtsratschef. Wie das im TecDAX und SDAX notierte Unternehmen mitteilte, wurde der... ► Artikel lesen | |
| SANOFI | 80,18 | -0,34 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi mit einem Kursziel von 95 Euro auf "Neutral" belassen. Analyst Richard Vosser wertet die Ergebnisse der Phase-II-Studien... ► Artikel lesen | |
| GSK | 24,960 | +0,44 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem Kursziel von 1700 Pence auf "Underweight" belassen. Mit Blick auf das erste Quartal liege er mit seinen Umsatzschätzungen... ► Artikel lesen | |
| ASTRAZENECA | 174,35 | +0,23 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 16000 Pence auf "Overweight" belassen. Richard Vosser rechnet mit einer starken Umsatzentwicklung... ► Artikel lesen | |
| TILRAY BRANDS | 5,600 | -0,36 % | Tilray Brands, Inc.: Tilray Expands Canadian Cannabis Portfolio with Launch of PORTAL, A New High Intensity Brand for the Experienced Consumer | TORONTO, April 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. company (Nasdaq: TLRY; TSX: TLRY) a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis... ► Artikel lesen | |
| DERMAPHARM | 43,950 | +2,09 % | EQS-PVR: Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Dermapharm Holding SE
Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
07.04.2026... ► Artikel lesen | |
| ZOETIS | 100,05 | -0,45 % | Zoetis Inc. to Acquire Animal Genomics Business from Neogen, Accelerating Precision Animal Health Innovation | Acquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide
PARSIPPANY... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,928 | -2,59 % | Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied | TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building... ► Artikel lesen | |
| CSPC PHARMA | 0,998 | -0,63 % | CSPC PHARMA (01093): UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY | ||
| TONIX PHARMACEUTICALS | 10,710 | +0,75 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and ... | Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,442 | +1,12 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| CANTOURAGE GROUP | 4,720 | +2,39 % | Original-Research: Cantourage Group SE (von NuWays AG): BUY | Original-Research: Cantourage Group SE - from NuWays AG
18.03.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,100 | +0,99 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| OPKO HEALTH | 0,980 | 0,00 % | OPKO Health, Inc.: OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 | WESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 64,12 | +0,83 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar |
Das Unternehmen EGETIS THERAPEUTICS AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,085 (+16,97 %) liegt der Kurs bei 0,586 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.